- Home
- VEEA vs LPTX Comparison
VEEA vs LPTX Comparison
Compare VEEA & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VEEA
- LPTX
- Stock Information
- Founded
- VEEA 2014
- LPTX 2011
- Country
- VEEA United States
- LPTX United States
- Employees
- VEEA N/A
- LPTX N/A
- Industry
- VEEA
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VEEA
- LPTX Health Care
- Exchange
- VEEA NYSE
- LPTX Nasdaq
- Market Cap
- VEEA 137.7M
- LPTX 119.6M
- IPO Year
- VEEA N/A
- LPTX N/A
- Fundamental
- Price
- VEEA $3.66
- LPTX $2.55
- Analyst Decision
- VEEA
- LPTX Strong Buy
- Analyst Count
- VEEA 0
- LPTX 3
- Target Price
- VEEA N/A
- LPTX $7.50
- AVG Volume (30 Days)
- VEEA 67.4K
- LPTX 335.2K
- Earning Date
- VEEA 02-23-2025
- LPTX 11-13-2024
- Dividend Yield
- VEEA N/A
- LPTX N/A
- EPS Growth
- VEEA N/A
- LPTX N/A
- EPS
- VEEA N/A
- LPTX N/A
- Revenue
- VEEA $140,035.00
- LPTX N/A
- Revenue This Year
- VEEA N/A
- LPTX N/A
- Revenue Next Year
- VEEA N/A
- LPTX N/A
- P/E Ratio
- VEEA N/A
- LPTX N/A
- Revenue Growth
- VEEA N/A
- LPTX N/A
- 52 Week Low
- VEEA $2.14
- LPTX $1.68
- 52 Week High
- VEEA $18.56
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- VEEA N/A
- LPTX 37.35
- Support Level
- VEEA N/A
- LPTX $2.88
- Resistance Level
- VEEA N/A
- LPTX $3.27
- Average True Range (ATR)
- VEEA 0.00
- LPTX 0.28
- MACD
- VEEA 0.00
- LPTX -0.06
- Stochastic Oscillator
- VEEA 0.00
- LPTX 12.71
About VEEA VEEA INC
Veea Inc is a company providing edge platform having extensive knowledge and expertise on content delivery and edge computing, and has brought a broad range of Wi-Fi, 4G/5G mobile wireless, and IoT products to market over the past two decades. It has first-in-class VeeaHub smart computing hubs integrate a full range of connectivity options, application processing power, and a full security stack to form an elastic edge computing platform with a dynamic connectivity and application mesh that can easily be deployed and centrally managed from the cloud.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .